U.S. FDA Determines Celliant(R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

Food and Healthcare Press Releases Tuesday July 25, 2017 18:00
LOS ANGELES--25 Jul--PRNewswire/InfoQuest
  • Hologenix, LLC's technology is first of its kind to secure joint FDA designations
  • Celliant-engineered products clinically proven to promote increased localized blood flow
  • FDA determination to usher in new era of performance fabrics, responsive textiles

Hologenix, LLC, maker of Celliant , the world's most advanced, clinically tested responsive textile technology, announced today that the U.S. Food and Drug Administration (FDA) has determined Celliant products are medical devices and general wellness products, as defined in Section 201(h) of the Federal Food, Drug and, Cosmetic Act. According to the FDA, Celliant products were determined to be medical devices because they temporarily promote increased local blood flow at the site of application in healthy individuals.

PureCare Elements: Lumen(R) Premium Celliant(R) Sheet Set: The first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

"Celliant-engineered products are the first of their kind that the FDA has designated as medical devices," said Seth Casden, Hologenix CEO. "Our technology can be used in everyday products – t-shirts, clothing, bedding, even airplane seats – to create an increase in local blood flow thereby increasing energy, boosting performance and speeding muscle recovery."

"We believe that Celliant is a truly disruptive technology that has transformational applications for textiles," Casden said. "We're currently evaluating additional applications of Celliant in the healthcare space, where, for example, people who suffer from diabetes might benefit from increased blood flow to body tissue."

Celliant-engineered products harness and recycle the natural heat emitted by human beings to boost performance and rebuild and recharge the human body after physical activity and while you sleep. Celliant is made of a patented blend of thermo-reactive minerals infused into the core of fiber used to create all types of textiles and fabrics so it does not wash or wear out. Products made with Celliant fabric absorb and convert body heat into infrared energy (IR) that is recycled back into skin and tissue in a safe, natural way. IR is a vasodilator, increasing blood flow to tissue and muscles throughout the body, which delivers vital nutrients and oxygen to the cells. The effect is clinically proven to help the body:

  • increase energy, endurance, stamina and performance,
  • recover faster from physical activity,
  • promote restful sleep and increased comfort.
Celliant is used in a diverse range of textiles and applications – apparel, bedding, wetsuits and veterinary products, including:
  • SIMA award winner, Xcel Infinity Comp TDC Full Suit with Celliant which uses Celliant to create the warmest wetsuit lining so you can surf longer and recover faster;
  • Salewa Puez TirolWool Celliant Half Zip Jacket that blends TirolWool, naturally warm, breathable and hydrophobic insulation from Imbotex, with Celliant to keep outdoor enthusiasts energized and warm all day long. Release date: Fall 2017;
  • ISPO award winner, Tecnica Mach 1 Pro Women Ski Boot, a ski boot made for women by women that uses Celliant and Lambswool Heat from Imbotex in its lining to address women's specific needs for warmth, comfort and performance on and off the slope. Release date: Fall 2017;
  • PureCare Elements: Lumen(R) Premium Celliant(R) Sheet Set, the first linen collection that uses Celliant to increase comfort and promote faster recovery while you sleep.

"Science has shown that infrared energy increases blood flow, improves muscle recovery and reduces long-term pain," said Dr. Michael R Hamblin, principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital. "The FDA's determination of Celliant products as medical devices and general wellness products will likely spur interest in infrared technologies and further development of garments and wraps that can positively impact people's well-being."

Celliant has been extensively researched, developed and clinically tested for both durability and effectiveness. Prominent institutions have conducted nine clinical trials to evaluate Celliant's performance including University of California Irvine, University of Calgary, UCI Long Beach Veterans Affairs Medical Center, Texas A&M University, Loyola University Chicago and Exponent. Celliant technology has been shown to increase tissue oxygen levels by eight percent at the site of applicationi.   Click here for NIH independent study on the benefits of IR on recovery.

About Celliant(R)

Celliant is a revolutionary, patented technology that harnesses and recycles the body's natural energy through the medium of fibers. Celliant's applied science utilizes a blend of minerals and proprietary ingredients that are embedded into the core of the fiber. Use of products containing this technology has been clinically proven to enhance tissue oxygen levels, improve athletic performance, sleep quality, health and wellness. Fibers, yarns and fabrics with Celliant technology can be found in some of the world's most recognized name brands. For more information, visit www.celliant.com .

About Hologenix, LLC

Founded in 2002, Hologenix, LLC, maker of Celliant technology, is committed to creating, developing and bringing to market products that enhance people's lives through new materials. They strive to deliver the future of healthy innovation through a variety of consumer categories. In addition to the United States, Celliant is designated as a Class I medical device in Canada, European Union, Australia and New Zealand. The Company continues to explore new territories and is currently running FDA-focused, clinical trials to expand into the medical product arena.

i Dr. Ian Gordon – University of CA, Irvine, Effect of Garment with 42% Celliant Fiber on TCP02 Levels and Grip Strength in Healthy Subjects. 2010
Contact: Julia Moore, +1-212-445-8160, Julia.Moore@webershandwick.com
Photo - http://mma.prnewswire.com/media/538683/PureCare_Sheets.jpg
Photo - http://mma.prnewswire.com/media/538684/Xcel_Infinity_Comp_Full_Suit.jpg
Photo - http://mma.prnewswire.com/media/538685/Tecnica_Mach_1_Pro_Women_Ski_Boot.jpg
Photo - http://mma.prnewswire.com/media/538686/Salewa_Puez_TirolWool_Celliant_Half_Zip_Jacket.jpg
Logo - http://mma.prnewswire.com/media/538687/Celliant_Logo.jpg

Latest Press Release

ESMO Publishes New Position Paper on Supportive and Palliative Care

ESMO, the leading professional organisation for medical oncology, published a position paper on supportive and palliative care [ https://doi.org/10.1093/annonc/mdx757 ], calling attention to the evolving and growing gap between the needs of cancer...

Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

The medical device company is transforming neurological treatments through its non-invasive focused ultrasound applications Koch Disruptive Technologies, a subsidiary of Koch Industries focused on finding and funding innovative and emerging companies,...

MediaTek Sensio: New Biosensor Solution Brings Health Monitoring to Smartphones

MediaTek Inc. today unveiled MediaTek Sensio(TM), the first 6-in-1 smartphone biosensor module. MediaTek Sensio is a powerful advanced health monitoring solution which makes it easy to track heart rate information, blood pressure trends, peripheral...

Merck Signs Distribution Agreement with Avanti(R) Polar Lipids

Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company's research lipids portfolio outside of the United...

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar levels in people with type 2 diabetes after six months.[1] The study looked at people with type 2...

Related Topics